News

  • Calmark CE marks and receives patent rights to new smartphone based diagnostic platform

    PRESS RELEASE – 15th July 2014

    Calmark CE marks and receives patent rights to new smartphone based diagnostic platform 

    • Calmark introduces hilda Neo System™, a smartphone based point-of-care diagnostic testing system
    • CE marking of system including hardware and software app obtained in June 2014
    • Patents that form basis for system’s IP granted in Sweden in July 2014
    • First rapid smartphone test on system to assist physicians in assessment of newborns immediately after birth

    Calmark CE marks hildaNeo System™, a rapid smartphone based system test to assist physicians in assessment of newborns immediately after birth. Calmark’s hildaNeo System™ is a point-of-care test for use on newborns in acute situations to enable quicker and more accurate decision support by physicians. The system combines innovative blood testing and smartphone technology into a diagnostic solution with a few minutes turnaround time from sample to result.

    In addition, two of Calmark’s novel patent applications for Calmark’s unique and innovative smartphone based software have been granted in Sweden. The two patents claims novel methods for detecting biomarkers in blood and other body fluids with a smartphone in a unique and novel diagnostic system solution. The inventors behind the innovation are Mathias Karlsson and Sofia Hiort af Ornäs, founders of Calmark Sweden AB, and Hjalmar Didrikson, Chairman of Calmark Sweden AB.

    Torbjörn Andersson, CEO of Calmark commented “We are very excited about bringing our new system to market; First to assist in assessment of newborn babies and subsequently for a number of applications to come. What used to require a lab can now be done with our disposable and a mobile phone.”

    Contact: Torbjörn Andersson, CEO, Calmark, mobile no. +46 70 242 36 63

    Press release as PDF: Press release Calmark 15th July 2014

    Calmark presents at IFCC WorldLab Istanbul 2014

    Linus Olson, Mathias Karlsson, and Lars-Olof Hansson are presenting Calmark hildaNeo System with three posters at IFCC WorldLab, 23-25 June 2014, one of biggest and most influential conferences in the clinical chemistry field.

    The poster “Colorimetric Lactate Dehydrogenase analysis using a fully integrated lab-on-a-chip and a smartphone at the point of care”, poster no. 0024 presents the Calmark hildaNeo System, a point of care test (POCT) for usage within neonatal medicine.

    The first weeks after birth are, in a global perspective, the period in life with the highest morbidity and mortality, with approximately 4 million deaths annually. Minimizing delay between onset of illness and start of treatment is crucial. New research have shown that the unspecific properties of Lactate dehydrogenase (LDH) offer a clinically important decision support when assessing neonatal patients in acute situations.

    The Calmark hildaNeo System offers a new POC platform suitable for use in a wide variety of professional health care settings.

    Calmark recruits new CEO

    As of today, Torbjörn Andersson is new CEO of Calmark Sweden AB. Torbjörn has over 25 years of experience of general management, product development and sales in the life science industry. Torbjörn holds a BSc in Biochemistry, and a MBA with honors from IMD business school in Lausanne, Switzerland. Mathias Karlsson will continue his work in Calmark as Medical Director.

    God jul & Gott nytt år

    Önskar vi på Calmark. Istället för julkort så donerar vi till Lilla barnets fond.

    CEO Mathias giving lunch seminar at Karolinska Institutet

    Calmark CEO Mathias will share his experience on the journey from the clinic and the lab to a venture capital funded medtech company.

    Nov 6th, 12-13, no pre-registration needed, but seats are limited.

    Lennart Nilssonsalen, Nobels väg 15a, Karolinska Institutet, Campus Solna

    New Calmark employee

    We are growing and as of this week Annika Österdahl is part if the Calmark team. Annika will focus on marketing and sales of Calmark’s current and future products.

    Calmark goes to San Fransisco

    Mathias Karlsson, founder and CEO, will represent Calmark at the Founders Club JPM Demo Day at Wilson Sonsini Goodrich & Rosati (WSGR), San Francisco, USA.

    Season greetings

    The year of 2012 has been exciting and eventful for Calmark. We have managed to CE mark our first product hilda NeoTM, started developing and CE marking a smartphone app and we’ve had several patents granted and participated in numerous studies.

    We want to thank everybody we’ve worked with during 2012 and lock forward to new exciting projects and collaborations in 2013. Instead of thanking everybody with Christmas presents we’ve chosen to contribute to Lilla barnets fond.

    Since we’ve outgrown our offices in Albanova we would also like to announce that we are moving to new facilities in Greenhouse labs at the Royal Institute of Technology in Stockholm.

    Merry Christmas and a Happy New Year!

     

    New scientific publication

    A new scientific paper on Lactate dehydrogenase in neonatal intensive care patients has been published in Acta Paediatrica. Read the article on PubMed (PMID: 22963670).

    SvD Näringsliv: Hjalmar Winblad on investment in Calmark

    Svenska Dagbladet, one of Swedens largest daily newspapers, publishes article based on interview with Hjalmar Winbladh on the opportunities when medical technology are combined with new innovations within IT and smartphones. Read the article here (in Swedish)